Introduction
T he abnormal accumulation of amyloid-β aggregates, due to the misprocessing of the amyloid precursor protein, is a characteristic pathophysiology of Alzheimer's disease [1] . With the proposed pathogenic role of amyloid-β, the ability to detect and map the extent of its deposition is an invaluable resource for monitoring disease progression and therapeutic effect. Based on this premise, a number of radiotracers targeted against amyloid-β have been developed and allowed for an objective and non-invasive measurement of this pathological hallmark with positron emission tomography (PET) [2, 3] . A carbon-labelled benzothiazole derivative, [ 11 C]Pittsburgh compound B ([ 11 C]PiB), was the first proposed selective amyloid-β imaging agent [4] and, to date, is the most extensively studied for both preclinical and clinical applications. Increased [ 11 C]PiB retention has been successfully employed to differentiate between prodromal, Alzheimer's disease (AD) and healthy individuals [4, 5] . Likewise in the preclinical realm, [ 11 C]PiB enables in vivo quantification of amyloid-β in transgenic animal models and has been effectively employed to monitor disease progression and measure treatment effect [6] [7] [8] .
The manifold successes of [ 11 C]PiB spurred the development of fluoro-labelled compounds to overcome the prohibitively short half-life of carbon-11 (20 min) and thereby facilitate wider availability and multiple uses of radiotracer productions. These agents include the fluorinated analogue of PiB, ([ 18 F ]flutemetamol) [9] [10] [11] [15] . These tracers all bind with high affinity to fibrillar amyloid-β as [ 11 C]PiB [16] and have similarly demonstrated in vivo detection of amyloid-β pathology in symptomatic patients and in animal models [17] [18] [19] . Despite this congruity, amyloid tracers display different imaging characteristics that arise largely due to their varying degrees of non-specific retention. While high non-specific white matter retention is a shared trait amongst amyloid tracers, it is generally more pronounced with more lipophilic fluoro-labelled compounds and results in lowered signal specificity [20] . Reduced contrast can present issues for the sensitive detection of low pathological burden or small alterations in plaque load and is especially pertinent in small animal imaging where sensitivity is restricted by the limited resolution of PET and the small size of the rodent brain. Based on this premise, the present study aimed to evaluate the sensitivity of [ 18 
Materials and Methods

Animals
To compare the sensitivity of [
18 F]FBB and [ 11 C]PiB, we investigated two animal models of cerebral amyloidosis with contrasting levels, distribution and subtypes of β-amyloid deposition relating to Bhigh^and Blow^tracer target states.
Amyloid tracers bind with high affinity to dense core plaques. For a high target state of dense fibrillar amyloid-β burden, we employed an aged double transgenic model, APPPS1-21 (n=6) [21] . These mice coexpress the human Swedish double APP mutation KM670/671NL and the human mutated PS1 L166P driven by the neuron-specific Thy-1 promoter element. Due to these mutations, APPPS1-21 mice undergo accelerated and severe disease pathogenesis. Amyloid-β deposition begins as early as 6 weeks of age [21] , and at later stages, these mice have extensive dense core plaque pathology. Wild-type littermates were used as controls (C57BL/6J, n=7).
For a low target state, we employed aged BRI1-42 mice (n=6). These mice express a BRI-Abeta42 fusion construct under the control of a mouse prion promoter. Human Aβ1-42 is fused to the BRI protein and, upon proteolytic cleavage, is secreted resulting in extracellular amyloid accumulation. BRI1-42 mice display parenchymal and vascular amyloid deposition starting in the cerebellum (3 months) and later in the forebrain (6 months) [22] . Plaques are predominantly diffuse in nature with dense core morphology observed almost exclusively in the cerebellum. The combination of relatively modest amyloid burden [23] and diffuse plaque subtype represents low target abundance for amyloid tracers intrinsically having greater affinity for dense fibrillar plaque. Wild-type littermates were used as controls (B6C3, n=6). All animals were 22-25 months at the time of imaging. We experienced a high dropout rate of mice, both transgenic and controls, due to the old age of the animals and their sensitivity to extended periods of anaesthesia. However, in total, five mice from the high signal cohort (two C57Bl/6J and three APPPS1-21) and eight mice from the low signal cohort (four B6C3 and four BRI1-42) successfully underwent both scan procedures. Animals that did not survive the first scan were replaced by aged-matched littermates for the second scan to maintain sufficient (n=6) group size. The animals were kept under environmentally controlled conditions (12- PET Data Acquisition, Reconstruction and Processing μPET imaging was conducted using a Siemens Inveon PET/CT system. For all scans, anaesthesia was induced by inhalation of isoflurane (5 % for induction and 2 % for maintenance during preparation and scanning) supplemented with oxygen. Tracers were injected via the tail vein in a fixed volume of 200 μl. During the scan, the core body temperature of the animals was maintained via a temperature-controlled heating pad. Upon intravenous injection of 7.98±0.62 MBq of [ 11 C]PiB, a 60-min dynamic acquisition was initiated. To exclude the involvement of decreased tracer delivery, we conducted dynamic [ 11 C]PiB scans and took the early uptake as a surrogate marker of perfusion. List mode data was originally rebinned into 33 frames following the scheme (12×10, 3×20, 3×30, 3×60, 3×150, 9×300). To investigate specific tracer retention after initial uptake, list mode data was additionally reframed into (1×1200, 1×1800, 1×600) with the second frame corresponding to a 20-50-min scan period taken for analysis. This time frame was determined from the dynamic data to provide the highest contrast between APPPS1-21 and wild-type (WT) mice. In the case of [ 18 F]FBB, tracer administration was again performed via intravenous injection, and after a conscious uptake period of 35 min, either a 15-or 25-min scan was acquired depending on the specific activity (and thus injected dose) in order to achieve noise equivalent counts in the images. This protocol was implemented based on a previous preclinical study with [ 18 F]FBB [19] and with support from in-house data with the closely related stilbene derivative [ 18 F] AV45 (unpublished data). Also, to explore the feasibility of a prolonged uptake period with [ 18 F]FBB scanning as performed in humans, the APPPS1-21 cohort underwent an additional [ 18 F]FBB scan with a 90-min uptake period. All details of imaging protocols are displayed in Table 1. PET data was reconstructed with two-dimensional ordered subset expectation maximization (OSEM2D) [24] algorithm using 4 subsets and 16 iterations following Fourier rebinning (FORE) [25] . The energy and timing window was set to 350-650 keV and 3.432 ns, respectively. The PET images were reconstructed on a 128×128×159 grid with a pixel size of 0.776×0.776×0.776 mm. Normalization, dead time, randoms, CT-based attenuation and single scatter stimulation (SSS) [26] corrections were applied. A 5-min CT was acquired subsequent to all PET scans using a 220°r otation with 12 rotation steps; voltage and amperage were set to 80 keV and 500 μA, respectively.
Volume-of-interest (VOI) analysis was performed on reconstructed images using PMOD v3.3 (PMOD Technologies, Switzerland). Individual PET images were first rigidly coregistered with their individual CT sequentially acquired with the aforementioned PET/CT scanners in order to correct for minor motion due to deep anaesthesia breathing or bed translation in the gantry from PET to CT. Next, these coregistered PET/CT images were then non-rigidly spatially normalized into the space of a predefined mouse brain MRI/CT template [27] by spatially matching the CT. Thereafter, extracerebral activity was removed through the use of a brain mask derived from the T2-weighted MR of the MRI/CT template whereby all voxels outside the brain mask were set to zero intensity and voxels inside the mask were unaltered. For an absolute measure of tracer uptake, normalized images were scaled according to the percent injected dose (tissue uptake [ k B q / c c ] /injected dose [kBq] ×100). Processed images were subsequently evaluated in a mouse brain VOI template (predefined on the aforementioned MRI/CT template), and tracer uptake values were extracted for each delineated VOI. With this approach, regional values are quantified as the average uptake over the total number of voxels in a VOI. To create visual representations of the relative uptake of tracers between diseased and healthy animals, average images were created for each genotype. Thereafter, a percent difference image was calculated by the f o r m u l a ( M e a n _ i m a g e T G − M e a n _ i m a g e W T ) / (Mean_image WT )×100.
Immunohistochemistry
After μPET scans, animals were sacrificed, and brain tissue was fixed, paraffin-embedded and cut into 5-μm coronal sections. De-waxed and rehydrated sections underwent tissue depigmentation in potassium permanganate, oxalic acid and water and were subsequently pretreated with 70 % formic acid for 10 min for epitope retrieval. Endogenous peroxidase activity was blocked by rinsing in 3 % hydrogen peroxide for 5 min. Thereafter, sections were incubated with mouse anti-amyloid primary antibody (JRF/AβN/25 1:15,000 1 h), HRP-labelled secondary antibody (anti-mouse, 30 min) and visualized with diaminobenzidine (DAB). Finally, the sections were counterstained with haematoxylin, dehydrated by submerging in a series of alcohol, fixed in xylene, mounted and coverslipped.
Virtual images were acquired using a Mirax Digital Slide Scanner (Zeiss), and image analysis was performed using the Definiens analysis software package v1.5. Regions of interest (ROIs) were manually delineated in accordance with Franklin and Paxinos atlas [28] , and for each ROI, the percentage of DABlabelled area was calculated. (Fig. 1a-c) . The whole brain was affected with the cortex presenting the highest burden (15.71±3.69 %, Fig. 1a ). Even the cerebellum, a region without appreciable transgene expression, demonstrated amyloid-β deposition (Fig. 1a, c (Fig. 2a, b) . In the case of [
11 C]PiB, uptake was significantly different in all regions investigated with the striatum and hippocampus (both p=0.001) revealing the highest significant differences to WT (Fig. 2a) . [ 18 F]FBB uptake was significantly higher in APPPS1-21 mice in all regions excluding the cerebellum. With [
18 F]FBB, the highest significance was revealed in the cortex and thalamus (both pG0.0001) (Fig. 2b) . (Fig. 3a) and [ 18 F] FBB (Fig. 3b) uptake in WT and APPPS1-21 mice.
Low Target State Forebrain regions displayed modest diffuse amyloid-β deposition (Fig. 1e, f) in the range of (0.24-1.47 %) (Fig. 1d) . The cerebellum exhibited the highest amyloid-β burden (4.27±1.39 %) and additionally displayed mature plaque phenotypes (Fig. 1d) (Fig. 2c, d ). A. Of the total high target state cohort (n=12), the regional uptake and distribution of tracer uptake was compared between a subset of animals (n=5) that had undergone all protocols longitudinally (WT n=2, APPPS1-21 n=3). In these five animals that, at this very advanced age, survived both the [ 11 (Fig. 4a) .
The in vivo cerebral distribution of both amyloid tracers showed poor correlation with ex vivo measures of amyloid-β (Fig. 4b, c) . In particular, for both tracers, there was a notable underestimation of plaque burden in the cortex by μPET measures.
To investigate the difference in contrast obtained for each tracer, we measured the percent difference in uptake between APPPS1-21 mice and WT for both [ 11 C]PiB and [ 18 F]FBB. With [ 11 C]PiB, relative differences in regional uptake between WT and APPPS1-21 mice were 108, 107, 114, 100 and 68 % for the striatum, cortex, hippocampus, 
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A. 11 C]PiB. However, it should be noted that due to lower variance in tracer uptake, the significance obtained between WT and APPPS1-21 mice was higher with [ 18 F]FBB. This is presumably due to the better count statistics obtained with a radiotracer based on F-18. A previous preclinical study found a similarly low contrast whereby only a 14.5 % difference between WT and t rans gen ic mice (5XFAD) was o bser ved w ith [ 18 F]florbetapir in comparison to a 21 % difference obtained with [ 11 C]PiB in the same mouse cohort [29] . Clinical comparisons of these fluoro-labelled amyloid tracers to [ 11 C]PiB have yielded analogous results [30, 31] with the noted exception of [ 18 F]AZD4694 [32] . As is the case in this study, the cortical distribution of fluoro-labelled tracers correlates well with [ 11 C]PiB, but the absolute difference between diseased and healthy subjects is comparatively lower. Specifically for [
18 F]FBB, a 56 % difference between AD and healthy controls was observed in comparison to a 75 % difference with [
11 C]PiB [31] . The disparity in imaging characteristics arises from differences in their physiochemical properties and can be attributed in a large part to the increased lipophilicity of fluoro-labelled alternatives [20] . Although this characteristic enhances the brain permeability of a compound, it incurs the cost of increased non-specific binding [33] . [ 11 C]PiB itself suffers from a relatively rapid metabolism [34] and nonspecific white matter retention [35] , but unlike a number of its F-18 counterparts, its metabolism does not yield brain penetrant radiometabolites (except in rat) [36] . In humans, [ 18 F]FBB has an estimated plasma half-life of 6 min and its A.
metabolism produces a number of brain penetrant radiometabolites [37] . Metabolism of [ 18 F]FBB is likely faster in mice, given the generally greater rate of metabolism in rodents. The resultant decrease in signal specificity due to cerebral uptake of both intact tracer and radiometabolites may limit the accuracy of quantification and, as evidenced here, lowers the dynamic range and thus the contrast between diseased and healthy animals. A common method to negate the effects of high non-specific binding is to prolong the uptake time allowing for a longer wash-out period of non-specifically bound tracer. A clinical protocol for [
18 F]FBB is based on this premise and involves a 90-min uptake period [31] . We employed a similar protocol in the APPPS1-21 mouse cohort, whereby mice received an i.v. injection of [
18 F]FBB, and following a 90-min uptake time, a 15-min static scan was acquired. Results from these scans (Fig. 6a ) demonstrated extensive accumulation of radioactivity in the skull bone, likely due to defluorination of the tracer. Therefore, such an approach is unsuitable for small animal imaging applications. The contribution of nonspecific retention to contrast has been described in relation to the binding of [ 18 F]florbetapir in 12-month APPPS1-21 mice [18] . In this study, ex vivo autoradiography with [ 18 F]florbetapir evidenced a 60 % difference between WT and transgenic mice in contrast to a 15 % difference obtained with in vivo μPET imaging. While the superior results are due in part to the higher resolution of autoradiography, they cannot account for this vast difference alone, thereby pointing to non-specific retention in vivo.
Although immunohistochemistry confirmed the high plaque load in APPPS1-21, the correlation between regional tracer uptake and regional quantification of amyloid-β was poor for both [
C]PiB and [
18 F]FBB. With immunohistochemistry, the amyloid-β burden observed in the cortex was almost 3-fold higher than that in the striatum, hippocampus and thalamus. However, from the μPET data, tracer uptake in the cortex is relatively lower than other forebrain regions. It is likely that the extensive amyloid deposition combined with the small size of the mouse brain precludes accurate quantification due to spillover and partial volume effects (PVE) in these very old APPPS1-21 animals with highly abundant plaque load. In this instance, uptake in the cortex is underestimated due to spillover of activity into adjacent regions. Indeed, in a previous longitudinal investigation of [ 18 F ]FBB binding in APP-swe mice, the application of PVE corrections to μPET data resulted in greater cortex to cerebellum uptake values and a higher congruence to ex vivo autoradiography and immunohistochemistry measures of plaque load [38] . In addition to PVE, binding of amyloid tracers to white matter [35] or sulfotransferase (SULT1E1) [39] may account for the discrepancies between in vivo and ex vivo measurements of plaque load.
We evidenced a lack of substantial accumulation of either [ 18 F]FBB or [
11 C]PiB in aged BRI1-42 mice. Plaques are predominantly diffuse in nature in the forebrain of these mice for which amyloid tracers have lower affinity [40] . Taken in combination with the low amount of amyloid-β, the forebrain may have presented too great a challenge for the tracers to have substantial retention. In contrast to forebrain regions, the dense core plaque pathology evidenced by immunohistochemistry in the cerebellum would be expected to yield an increased in vivo signal. However, the cerebellum did not demonstrate increased uptake in BRI1-42 mice either in relation to other regions or to their WT. Once more, this may be related to reduced sensitivity as a consequence of non-specific retention as outlined previously. The cerebellum has a high content of white matter and thus may be heavily influenced by the effects of high non-specific white matter retention. The spatial resolution of μPET precludes the delineation of white matter tracts in the cerebellum, and thus the specific contribution cannot be further investigated. Such enhanced cerebellar uptake has been described in preclinical investigations of [ 18 F]flutemetamol [36] . A secondary issue to consider is the contribution of tracer delivery to the brain. Previous failures to quantify amyloid-β in transgenic models have cited cerebral blood flow disturbances as a causative factor for lack of specific amyloid tracer binding. This is especially important in BRI1-42 animals, as they develop congophilic amyloid angiopathy [22] , which is known to cause disturbances in the cerebral vasculature and may lead to modifications of cerebral blood flow [41] . However, analysis of the early time frames from the dynamic [ 11 C]PiB scans in these mice (Fig. 6b, c) does not support altered perfusion as there were no significant differences in the initial uptake between genotypes. Lastly, it has been reported that amyloid plaques in animal models possess fewer high affinity binding sites for amyloid tracers than human plaques due to conformational and compositional differences [7, 42] . In this regard, biochemical differences in plaque composition may account for the lack of tracer binding in BRI1-42 mice in comparison to the significant retention in APPPS1-21 cohort. Such model differences in plaque pathology, in addition to the described sensitivity issues, are the likely cause of early disappointing results with amyloid imaging in animal models [42, 43] . Previous studies that investigated multiple models of transgenic mice with the same methodology have also reported differences in in vivo tracer binding related to variations in plaque structure. In a longitudinal comparison of [ 11 C]PiB binding in APP23, Tg2576 and APPPS1(dE9) mice, increased tracer binding due to increasing amyloidosis was only observed in APP23 mice [17] . In another comparison of [
11 C]PiB binding in ageing APP23 and APPPS1-21 mice, both models demonstrated increasing tracer uptake with worsening amyloidosis [17, 44] . Of interest, while amyloid-β burden in both models was within a similar range, APP23 mice demonstrated a BP ND approximately five times higher than that of APPPS1-21 mice. Both studies concluded that the relatively large dense core plaques present in APP23 mice were the underlying source of the higher [
11 C]PiB binding in comparison to other models [44] . Thus, while amyloid imaging is indeed feasible in animal models, it is highly dependent on the model employed and the type of plaque pathology at the age of imaging.
Our study into the sensitivity of amyloid tracers is limited in the respect that only a single time point was investigated, and that this time point was an old age with a high pathological burden and additionally a high mortality rate. 
